The Bleeding Edge of Discovery: What does the next decade of myeloma care look like? In this first installment, Dr. Tania Small brings together three of the world’s foremost experts to explore the breakthroughs redefining hope in multiple myeloma. From minimal residual disease (MRD) as a new regulatory endpoint to the research of immune-based therapies and the transformative potential these may hold, the panel dissects how science is accelerating toward the possibility of a functional cure. They also tackle some of the field’s toughest questions: how to sequence therapy in an era of quads, bispecifics, and antibody-drug conjugates, and how to close the survival gap for underrepresented populations by translating biology into equitable access.
Highlights include:
• How MRD is reshaping drug development and accelerating innovation
• The evolution of next-generation and targeted therapies with the goal of achieving deeper and more durable remissions
• New thinking on “hit hard early” vs “save the best for last” treatment strategies
• The impact of race, biology, and access on outcomes—and what’s changing that trajectory
If you want to understand the science, urgency, and humanity driving today’s breakthroughs, this episode is your front-row seat to the bleeding edge of discovery.
About the Experts
Dr. Paul Richardson
Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews.
Dr. Richardson is a paid consultant for BMS.
Dr. Joseph Mikhael
Dr. Joseph Mikhael has revolutionized and broadened access to world-class myeloma care globally through his pioneering leadership at TGen and the International Myeloma Foundation and as principal investigator of numerous groundbreaking clinical trials, setting new benchmarks in innovation, impact, and equity. Celebrated as a dynamic champion for underserved communities, an award-winning educator, and a masterful communicator, Dr. Mikhael has authored over 150 influential scientific articles and was recently recognized among America’s Top 100 Doctors for his transformational contributions to the field.
Dr. Mikhael was not compensated for his participation.
Dr. Mecide Gharibo
Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals.
Dr. Gharibo is an employee of BMS.